Bullboard - Stock Discussion Forum Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

Add To Watchlist

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > New September company presentation

View:

Post by Quentin30 on Sep 24, 2024 1:38pm

New September company presentation

just for a heads up, new presentation available at ONCY website.

First time I think I've ever seen any sales projections from ONCY, from which one might deduce annual cost per patient is approx 200k. although their own graph doesn't suggest any revenues UNTIL 2028...

till then... guess who's payng the bills.?

197

Comment

Comment by m00nsh0ts on Sep 24, 2024 4:31pm

$2,400,000,000÷55,000 = $43,636.36

Comment

Comment by Noteable on Sep 24, 2024 6:10pm

Now for the real facts ... Demand is hot for big results in key markets like mBC with an unmet treatment need. As for Big Pharma, the emphasis now is on finding therapies that have been de-risked with human data, as ONCY has been demonstrating over time, and as had been accomplished and reported on today in HR+/HER2- Breast Cancer. Analysis shows that around 122,000 HR+/HER2- mBC ...more

103

Comment

Comment by Noteable on Sep 24, 2024 6:46pm

Facts : Analysis shows that around 122,000 HR+/HER2- mBC patients will be ready for pelareorep + paclitaxel treatment in the combined United States and EU-27 global regions. Using the modeling that Kirk Look referenced in the Cantor chat and translating that into the above 122,000 mBC patients, peak pelareorep annual sales would reach approximately US$5.89 Billion in HR ...more

102

Comment

Comment by inthno on Sep 24, 2024 7:22pm

A quick correction for peak sales according to the new onc investor presentation from page 8. 8 Pelareorep Potential Peak Sales: $2.4 Billion

Comment

Comment by Noteable on Sep 24, 2024 7:57pm

soon ....

Comment

Comment by Noteable on Sep 24, 2024 8:16pm

maybe better stated as... soon enough... given the recent results and forthcoming planned clinical trial outcomes and result expectations

Comment

Comment by Noteable on Sep 24, 2024 8:47pm

well maybe Bigfoot to you ... realistic near term expectations for the rest of us

Comment

Comment by Quentin30 on Sep 25, 2024 4:58pm

No correction needed - My figures were for the US ONLY. It is expected that treatment would fetch a premium in the US, which I calculate from ONCY's slidedeck to be around 200k/yr. The cost in EU will be considerably less...

Comment

Comment by Quentin30 on Sep 25, 2024 4:08pm

Just an observation, but since when does a PROJECTION become a FACT ?? not a fact Noteable, but an expectation from Management... lets stop telling things aren't facts shall we... FACT : ONCY presents amazing data and the pps craters even further... does that signal success ?

Comment